| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCC3 |
| Uniprot No | O15438 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCC3重组蛋白的3篇参考文献的简要信息：
---
1. **文献名称**: "Functional characterization of recombinant human ABCC3/MRP3 in drug transport and ATP hydrolysis"
**作者**: Hiroshi Suzuki, et al.
**摘要**: 该研究通过昆虫细胞表达系统制备了重组人ABCC3蛋白，分析了其在药物转运中的功能。实验表明ABCC3可介导多种有机阴离子底物的外排(如胆汁酸和化疗药物)，并揭示了其ATP依赖性转运机制，为理解ABCC3在药物代谢和肿瘤耐药中的作用提供了依据。
---
2. **文献名称**: "Role of ABCC3 in multidrug resistance of colorectal cancer cells: Insights from recombinant protein expression and CRISPR/Cas9 knockout models"
**作者**: Maria T. Donner, et al.
**摘要**: 研究通过重组ABCC3蛋白表达结合基因编辑技术，探究其在结直肠癌细胞耐药中的作用。结果显示，ABCC3过表达显著增强细胞对5-FU和奥沙利铂的抗性，且重组蛋白的转运活性与细胞内药物浓度变化直接相关，提示其作为潜在治疗靶点。
---
3. **文献名称**: "Structural and functional analysis of ABCC3 using recombinant protein purified from mammalian cells"
**作者**: James K. Liao, et al.
**摘要**: 该研究在HEK293细胞中表达并纯化重组ABCC3蛋白，结合冷冻电镜解析其三维结构，揭示了底物结合域的构象变化。功能实验证实ABCC3对特定药物(如甲氨蝶呤)的亲和力受结构域间相互作用调控，为设计ABCC3抑制剂提供了结构基础。
---
(注：以上文献信息为示例性内容，实际文献需通过学术数据库查询。)
**Background of ABCC3 Recombinant Protein**
ABCC3 (ATP-binding cassette subfamily C member 3), also known as multidrug resistance-associated protein 3 (MRP3), is a membrane transporter protein belonging to the ATP-binding cassette (ABC) superfamily. It plays a critical role in cellular detoxification and efflux of endogenous and exogenous compounds, including conjugated metabolites, drugs, and toxins. ABCC3 is primarily expressed in organs such as the liver, intestine, and kidney, where it localizes to the basolateral membrane of epithelial cells, facilitating the export of substrates into systemic circulation or extracellular fluids. Its substrates include glucuronide and glutathione conjugates, bile acids, and certain chemotherapeutic agents, contributing to drug resistance in cancer cells and influencing pharmacokinetics.
Recombinant ABCC3 protein is produced using *in vitro* expression systems (e.g., mammalian, insect, or bacterial cells) to enable functional and structural studies. This engineered protein retains key features of native ABCC3. such as ATPase activity and substrate-binding capacity, allowing researchers to investigate transport mechanisms, substrate specificity, and interactions with therapeutic agents. Mammalian expression systems (e.g., HEK293 or CHO cells) are often preferred to ensure proper post-translational modifications (e.g., glycosylation) and membrane localization.
ABCC3 recombinant protein is pivotal in drug discovery and toxicology. It aids in identifying inhibitors to overcome multidrug resistance in cancer, evaluating drug-drug interactions, and modeling hepatic/renal excretion processes. Additionally, it serves as a tool for elucidating ABCC3’s role in metabolic disorders, cholestasis, and inflammation. Studies using purified ABCC3 have advanced structural biology efforts, including cryo-EM analyses, to map its transmembrane domains and nucleotide-binding sites.
Overall, ABCC3 recombinant protein is essential for dissecting its physiological roles, developing targeted therapies, and improving drug safety profiles through mechanistic insights into transporter-mediated processes.
×
